An invitation-only circle of founders, investors, and leaders united by commerce, conscience, and legacy.
Recommend a MemberWhat Is Genesis Business Humanity
Genesis BH exists at the intersection of capital, character, and cause.
We are a private, invitation-only global club for those who have earned their seat at the highest table.
Genesis BH is built on a singular conviction: the most powerful networks are not the largest ones. They are the most intentional. Every member is curated. Every connection is meaningful. We bring together exceptional founders, investors, family office principals, and visionary leaders, committed to excellence, integrity, and the belief that business and humanity are not competing forces.
Different industries. Different stages. Shared standards.
Here's a snapshot of what is being built inside.
Membership in Genesis BH is earned, not purchased.
Direct access to exclusive investment rounds in pioneering companies, pre-screened, founder-led, and presented before they reach the broader market. Genesis has reviewed about 200 companies in 3 years and approved 5.
See upcoming events →
As Genesis expands across the US, we are introducing local chapters for members in each region. Miami and New York/New Jersey are active. Look forward to more local events, or help us establish your own chapter.
See upcoming events →
Genesis is not a conference you attend once and forget. It is a living social network of private dinners, immersive gatherings, chapter events, and experiences designed for people who have earned their place in the room.
Get your deals →
Direct access to Israel's most innovative companies in technology, cybersecurity, AI, and defense, presented exclusively to Genesis BH members before reaching the broader market.
Become a member →
Direct exposure to curated Israeli tech, cyber, and innovation deal flow: opportunities unavailable through conventional channels.
Become a member →
White-glove service on demand. VIP dining reservations, private transportation, exclusive hotels and curated stays, personal travel planning, and bespoke experiences.
Get your deals →
Helping businesses and companies get their digital materials and presence out there. Our Digital division, with a powerful team, creates high-end videos, presentations, websites and all the other materials you need to look your best.
Click to learn more →
Direct partnerships with premier health, recovery, and rejuvenation providers give members access to world-class wellness services unavailable through standard channels.
Get your deals →
Private dinners, closed-room briefings, leadership summits, and curated experiences across the U.S. and Israel.
Get your deals →
Membership Privileges
Beyond the room and the deal flow, membership comes with privileges you won't find on any public list: partner offers, complimentary access, and evenings around a chef's table.
Preferred rates and private offers from Genesis partner hotels, restaurants, services, and products.
Complimentary entry to Genesis member evenings and selected chapter gatherings throughout the year.
Intimate dinners prepared by acclaimed chefs, seated for a small group of members and their guests.
First access to Israel Innovation Trips, the Annual Gala, and other limited-seat experiences before they open to guests.
Bring a guest to selected events and introduce the people you trust to the Genesis circle.
Priority booking and member rates with Genesis health, recovery, and rejuvenation partners.
Genesis Business Humanity is an exclusive, invitation-only club for exceptional leaders, investors, and founders who back the companies that move the world forward. With pro-Israel, pro-USA and pro-humanity values, we fund what matters, build what lasts, and foster a high-impact community of high-caliber executives.
The Genesis app gives members full access to the club ecosystem from anywhere in the world. Browse the member directory, RSVP to private events, track portfolio companies, and stay connected to every chapter.
Inside Genesis, capital meets cause. Members co-invest in Israeli and American companies that are solving real problems, advancing technology, and creating social change, alongside people they trust, in rooms that are closed to the public.
Members Only
Genesis Films
Star of Genesis Recordings
Event Recaps
From the Blog
Member Highlight
Editor’s Note: Another in the series on the people behind Genesis, this one from the clinical side. It is built from Dr. Fedder's professional record and public reporting.…
Member Highlight
Editor’s Note: Another in the series on the people behind Genesis, this one from the clinical side. It is built from Dr. Fedder's professional record and public reporting.
Every medical device company eventually runs into a question it can't answer from the inside: would a surgeon actually use this? The answer decides whether a product earns a place in the operating room, and it almost never comes from the company that built it.
Dr. Ira Fedder spends his working life on the other side of that question. He is a fellowship-trained orthopaedic spine surgeon with more than 35 years of clinical experience, a Genesis member and part of the medical advisory board behind Genesis MedTech.
His practice covers operative and non-operative care of spine and neck conditions, so he sees the full range of options a patient has, which is exactly the context any new device has to compete in. That breadth matters in a device conversation, because a surgeon's day is made of trade-offs, and a product is judged against them. Public reporting has described his clinical focus as including cervical disc herniation, myelopathy, cervical stenosis, lumbar stenosis and sciatica. He is affiliated with University of Maryland St. Joseph Medical Center in Towson, Maryland, and has been named a Top Doctor in Spine Surgery by Baltimore magazine.
He has also advised a device company directly. Becker's Spine Review reported in 2013 that Tyber Medical, a New Jersey medical device company, added him as a surgeon advisor. For a founder, that kind of experience is practical, and here is why.
A clinical advisor can answer what engineers and investors can't. Where in the procedure does this device sit? What does it replace, and what would make a surgeon change a technique they have used for years? What evidence would a colleague need to see before trying it? Those are the questions a hospital committee will ask, and a founder who has already heard them from a practicing surgeon can answer them calmly.
That matters because hospitals don't buy on regulatory clearance alone. A value analysis committee of clinical and administrative staff reviews each new product. Clinicians assess how it would be used, and administrators weigh the cost against clinical, patient and process outcomes. So clinical credibility sits right in the middle of the purchasing decision, and a founder whose product has never faced a practising surgeon's questions meets them for the first time in front of the committee.
Reimbursement raises the stakes. A hospital can only use what it can be paid for, and if no suitable billing code exists, the application for a new CPT code can take up to 24 months. How clinicians describe a procedure, and where a device fits inside it, shapes how that case gets built.
The same goes for investors reading a medical deal. It is easy to tell a clinical story and much harder to test one. Claims about clinical benefit sound equally confident in every pitch, and the people best placed to test them are the ones who treat patients. A board of working clinicians gives a medical company a way to check its clinical story before capital or customers depend on it.
That is the job of the advisory board at Genesis MedTech, a co-ordinated market entry programme for medical device, health-tech and software companies that takes them from first market assessment to first signed contract. Alongside the partners, six practising physicians and clinical leaders help shape how each product is positioned for clinical adoption, reimbursement alignment and health system credibility. Dr. Fedder's spine expertise is one part of a board that spans pain medicine, internal medicine and nephrology, dentistry and orthopedic spine surgery.
The partners bring the commercial side: group purchasing organisation relationships, health system contracting and enterprise sales experience. The advisory board brings the clinical side, which is the half a founder is least likely to have in house. You need both, because a product can satisfy a purchasing contract and still fail to win a surgeon's confidence, or win the surgeon and stall at purchasing.
For a founder, that means physicians with decades in practice can look at how your product is positioned before it meets a hospital committee. For an investor, it is a reason to trust that the clinical case behind a medical company has been looked at by people who treat patients. If you are building a medical device, health-tech or software company and want that perspective on your US plans, write to the Genesis team at amiel@genesisbh.net or ranny@genesisbh.net, or visit www.genesisbh.net. A short note about the product and the stage it has reached is enough to start.
Business
Discover how Genesis MedTech helps medical device companies navigate the complexities of the U.S. healthcare market and turn regulatory clearance into commercial success.
Business
Editor’s Note: If you have ever watched a cleared product sit unanswered in a hospital inbox, this one is for you. The team named below is current as of October 2026.
The clearance finally came through. Your device is legal to sell in the United States. So you start contacting hospitals, and almost nobody replies. The few who do reply ask questions nobody prepared you for. Which group purchasing organisation are you on contract with? Has the product been through a value analysis committee? Which billing code does a hospital use when it uses your device? Every one of those questions points at a part of the US healthcare system that has nothing to do with how good your product is.
If that is where you are, the product isn't the problem. US medical device market entry is a structural challenge, and the companies that move fastest treat it like one from the start. Genesis MedTech, a division of Genesis Business Humanity, was built to take them through it.
Here is what is going on. Clearance tells a hospital that a device is legal to sell. It doesn't tell the hospital to buy it. Between clearance and a first contract sit gatekeepers who decide on more than product quality.
The first is the group purchasing organisation, or GPO, which negotiates supply contracts for many hospitals at once. A study published in JAMA Health Forum in September 2026 found that just three of them, Vizient, HealthTrust and Premier, were the primary GPO for more than 80% of US hospitals in 2024. Inside the hospital, a value analysis committee of clinical and administrative staff weighs each new product's cost against its clinical, patient and process outcomes. Integrated delivery networks, which are groups of hospitals and clinics run as one health system, add their own financial, operational and clinical criteria on top. The GPO and the health system are separate processes that call for separate relationships, and a contract with one doesn't open the door at the other.
Reimbursement is the next gate, because a hospital can only use what it can be paid for. Clearance doesn't make a device billable. Hospitals are paid through a coding framework, and if no suitable CPT or HCPCS code exists, the application for a new CPT code can take up to 24 months. US health systems also expect domestic accountability at every point in the supply chain, so distribution, billing, a legal entity and in-market representation are prerequisites too. Handled one at a time, each of these adds its own delay.
Genesis MedTech closes those gaps as a co-ordinated market entry programme for medical device, health-tech and software companies. It doesn't hand over a report and step back. The Genesis MedTech team builds, sells and delivers alongside your company until your product is moving.
The programme starts with an honest evaluation of your product's US fit across regulatory pathway, reimbursement positioning and competitive landscape. Target health systems and GPOs come next, chosen from direct institutional knowledge rather than secondary research, followed by a sequenced strategy and the commercial build itself: GPO contracting, IDN engagement, value analysis navigation and enterprise sales. The reimbursement case is built alongside the regulatory submission, so no months are lost waiting.
What makes it work is the people. Dan Romano spent nearly 30 years in healthcare, including more than 20 years with Arjo/Getinge Group and Zimmer Biomet, and founded HSUS in 2016 to help companies accelerate US market adoption. Don Webster, a former Regional VP at Vizient, builds the GPO and IDN relationships that open procurement. Geoff Rohrer, a former VP of Sales at two top-25 medical device companies, leads enterprise sales execution. Jon Berger, a middle market investment banker, connects companies to capital. And a medical advisory board of six practising physicians and clinical leaders, including Dr. Joseph Pergolizzi, helps shape how each product is positioned for clinical adoption and health system credibility.
Genesis MedTech suits a company with a validated product, early clinical evidence and a genuine commitment to a durable US commercial presence. It holds particular relevance for Israeli and international companies, given Genesis's direct connections to global innovation ecosystems, and it is open to any company that meets those criteria. To talk through your US market entry, write to the Genesis team at amiel@genesisbh.net or ranny@genesisbh.net, or visit www.genesisbh.net.
This article is for general information only and does not constitute investment, tax or legal advice. Past performance is not a guarantee of future results. Please consult your own professional advisors before making investment decisions.
Investment
As Israel and the U.S. head to the polls, decades of market data show why certainty matters more than who wins.
Investment
Editor’s Note: This article was written on October 19, 2026, ahead of Israel's Knesset election on October 27 and the U.S. midterm elections on November 3. Market figures reflect research available at the time of writing. Genesis BH is nonpartisan and takes no position on any party or candidate. Our aim is to help members think clearly about markets, not to comment on politics.
In the space of eight days, two of the democracies that matter most to our members go to the polls. Israelis vote for the 26th Knesset on October 27, and Americans head to the midterms on November 3. For an investor community that lives between Miami and Tel Aviv, that is a lot of headlines, a lot of opinions and, understandably, a lot of questions. The most common one we hear: Should I be doing something with my investments before the votes are counted? History offers a surprisingly calm answer. Elections move markets, but rarely in the way the noise suggests, and almost never for as long as the noise lasts.
Markets don't vote for a party. They vote for certainty.
This year's Knesset election is unusual on its own terms. It is the first time since 1988 that a Knesset has served its full four-year term, and official results are expected around November 4. Polls describe a race too close to call. The Tel Aviv Stock Exchange's own research unit recently looked at the ten Israeli elections since 2003 and found a clear pattern:
In other words, the market does its worrying in advance. Local stocks slipped in early October and underperformed global markets, which TASE economists read as investors bracing for a possible stalemate and even another round of voting. By election day, much of that risk is already in the price.
Longer-term research points the same way. Studies covering more than 60 years of Israeli elections have found that stock returns were, on average, higher in the period after elections than before them. And Israel's market has shown remarkable resilience through far bigger shocks than a ballot: in the Hebrew year that just ended, the TA-35 gained roughly 40%, well ahead of the S&P 500.
Israeli investors also have a particular reason not to over-read political drama. Since 1999 the country has held more than ten general elections, including four in two years. Many local market veterans have long argued that the economy, led by its private and tech sectors, responds more to global markets, inflation and interest-rate decisions than to who sits in the Prime Minister's office.
On the American side, the pattern is just as well documented, and it has a twist.
2026 has already broken the mold somewhat. Fidelity notes that U.S. stocks have held up this year despite worries about oil prices, tariffs and possible rate hikes. That is a useful reminder: the election calendar is one input, not a forecast. As Fidelity's strategists put it in plain terms, elections have been a supplementary driver of returns, not the core one.
None of this means elections are irrelevant. They matter most not to the index, but to specific corners of a portfolio:
1. Don't trade the headlines. The data in both countries suggests that the pre-election dip and the post-election recovery tend to cancel out within months. Selling into the noise often means locking in the worst part of the cycle.
2. Separate politics from policy. Ask what would actually change for a business or asset you hold, not which candidate you prefer.
3. Review your currency exposure. Cross-border investors should know how much of their portfolio is effectively a bet on the shekel-dollar rate.
4. Think in 12-month windows, not election nights. Historically, the year after the vote has been where the opportunity shows up.
5. Keep some dry powder. Volatility is uncomfortable, but for patient investors it is also where valuations become more attractive.
6. Talk it through. Elections are a natural moment to revisit allocation and goals with your advisors, calmly and on your own timeline.
Our members sit at the intersection of two economies that have repeatedly shown they can absorb political turbulence and keep growing. Israel's innovation engine and America's depth of capital don't switch off on election day. The ballot box will decide who governs. It is far less likely to decide how your portfolio performs over the next five or ten years. That still comes down to the quality of the opportunities you choose, the discipline you bring and the partners you invest alongside. Genesis BH connects high-net-worth investors with curated opportunities across the U.S. and Israel. To learn more about membership, visit www.GenesisBH.net.
This article is for general information only and does not constitute investment, tax or legal advice. Past performance is not a guarantee of future results. Please consult your own professional advisors before making investment decisions.
Upcoming events, portfolio news and member stories, once a week.
Genesis BH Club is not for everyone. But for the right person, it can be everything.
